Know Cancer

forgot password

PET Using Hormone Receptor Ligands in Breast Cancer

18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

PET Using Hormone Receptor Ligands in Breast Cancer

Inclusion Criteria:

- Male and Female patients

- Aged 18 or older at the time of breast cancer diagnosis

- Patients with invasive breast cancer at least 1 cm in size. Patients who have had a
prior surgical excision are eligible provided there is a residual of at least a 1 cm
area suspected on imaging studies.

- Histopathologic review at MSKCC confirming diagnosis of invasive breast cancer
(ductal, lobular, or inflammatory breast cancer).

- Patients who are operative candidates. Patient will have surgery to include either
mastectomy or lumpectomy. Radiologic assisted excisions such as needle localization
are also eligible.

- Patients with bilateral breast cancer are eligible.

- Patients with metastatic cancer, provided they need surgical biopsy.

- Patients who are undergoing sentinel node mapping (day before or sameday mapping).

- Patient must sign informed consent.

Exclusion Criteria:

- Previous or concurrent malignancy (except basal and squamous skin cancer and stage 0
cervical cancer)

- Patients who are pregnant or nursing

- Patients unable to tolerate PET or PET/CT

- Patients with known active infection, autoimmune or inflammatory disease such as
sarcoidosis, and rheumatoid arthritis.

- Patients with non invasive breast cancer such as DCIS.

- Patients who have received prior radiation therapy to the affected breast.

- Patients who have received prior chemotherapy, including neoadjuvant chemotherapy or
hormonal therapy for breast cancer.

- Patients living in a residential care or correctional facility.

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To use estrogen-like ligands labeled with positron emitters to preoperatively evaluate the estrogen receptor (ER) status of breast cancer on PET imaging.

Outcome Time Frame:

conclusion of the study

Safety Issue:


Principal Investigator

Mary Gemignani, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

November 2006

Completion Date:

November 2013

Related Keywords:

  • Breast Cancer
  • PET imaging
  • invasive breast cancer
  • Breast Neoplasms



Memorial Sloan Kettering Cancer Center New York, New York  10021